Guggenheim lowered the firm’s price target on Eledon Pharmaceuticals (ELDN) to $8 from $9 and keeps a Buy rating on the shares following the Q3 report last week. In addition to “routine incrementally positive adjustments,” the firm is also incorporating the dilution from the recent fund raising, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals: Promising Kidney Transplant Program and Strong Financial Position Support Buy Rating
- Eledon Pharmaceuticals reports Q3 EPS (21c), consensus (25c)
- Eledon Pharmaceuticals options imply 14.1% move in share price post-earnings
- Eledon Pharmaceuticals Announces $46.5M Public Offering
- Eledon prices 15.15M shares at $1.65 in underwritten public offering